Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1938]

Dasatinib-blinatumomab combination for the front-line treatment of adult Ph...

Prof Robin Foa - University of Rome, Rome, Italy

Dasatinib-blinatumomab combination for the front-line treatment of adult Ph-positive ALL patients ( Prof Robin Foa - University of Rome, Rome, Italy )

Dose escalation of REGN1979 in patients with relapsed and refractory B-NHL

Prof Max Topp - University of Würzburg, Würzburg, Germany

$Dose escalation of REGN1979 in patients with relapsed and refractory B-NHL ( Prof Max Topp - University of Würzburg, Würzburg, Germany )$

CD-19 mutation frequency after blinatumomab treatment is lower than after CAR T...

Dr Michaela Kotrova - Universitätsklinikum Schleswig-Holstein, Kiel, Germany

CD-19 mutation frequency after blinatumomab treatment is lower than after CAR T-cell therapy ( Dr Michaela Kotrova - Universitätsklinikum Schleswig-Holstein, Kiel, Germany )

ADMIRAL trial results: Gilteritinib versus salvage chemotherapy in patients...

Prof Alexander Perl - University of Pennsylvania, Philadelphia, USA

$ADMIRAL trial results: Gilteritinib versus salvage chemotherapy in patients with FLT3-mutated relapsed/refractory AML ( Prof Alexander Perl - University of Pennsylvania, Philadelphia, USA )$

Multiple myeloma science from EHA 2019

Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France

Multiple myeloma science from EHA 2019 ( Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France )

CAR T-cell therapy for treating acute leukaemia

Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France

CAR T-cell therapy for treating acute leukaemia ( Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France )

Selinexor plus cytarabine and idarubicin in patients with relapsed/refractory...

Prof Walter Fiedler - University of Hamburg, Hamburg, Germany

$Selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia ( Prof Walter Fiedler - University of Hamburg, Hamburg, Germany )$

ECHELON-1 study 3 year update: Frontline brentuximab vedotin with chemotherapy...

Dr Andrea Gallamini - Centre Antoine Lacassagne, Nice, France

ECHELON-1 study 3 year update: Frontline brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma ( Dr Andrea Gallamini - Centre Antoine Lacassagne, Nice, France )

Controlling CRS-related coagulopathy improves the safety of CAR T-cell therapy...

Dr Heng Mei - Huazhong University of Science and Technology, Wuhan, China

Controlling CRS-related coagulopathy improves the safety of CAR T-cell therapy for MM ( Dr Heng Mei - Huazhong University of Science and Technology, Wuhan, China )

ICARIA results: Treating RRMM patients with isatuximab, pomalidomide and low...

Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA

ICARIA results: Treating RRMM patients with isatuximab, pomalidomide and low-dose dexamethasone ( Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA )

HORIZON update: Using melflufen to treat RRMM patients refractory to...

Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA

$HORIZON update: Using melflufen to treat RRMM patients refractory to daratumumab and/or pomalidomide ( Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA )$

PET after 2 cycles of ABVD in patients with early-stage favourable Hodgkin...

Michael Fuchs - University Hospital of Cologne, Cologne, Germany

PET after 2 cycles of ABVD in patients with early-stage favourable Hodgkin lymphoma ( Michael Fuchs - University Hospital of Cologne, Cologne, Germany )

More from ecancer